secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001104659-25-049454
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started
--------------------------------------------------------------------------------

- Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.
- Cash, equivalents, and securities $185.8M as of March 31, 2025, down from $220.1M; estimated runway into Q4 2026.
- First patient dosed in Phase 1 CALiPSO-1 trial of CNTY-101 for autoimmune disease; clinical data expected by end of 2025.
- CNTY-308 (CD19-targeted CAR-iT) on track to enter IND-enabling studies mid-2025.
- R&D expenses increased to $26.6M from $23.4M due to clinical trial costs and preclinical program advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/0001104659-25-049454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/tm2514971d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-049454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer